BrightSpring Health Services: The PE Roll-Up That Actually Compounded

I. Introduction & Episode Roadmap

On the morning of January 26, 2024, a company that had spent five years inside the Kohlberg Kravis Roberts machine walked onto the Nasdaq floor and was politely mugged. BrightSpring Health Services had told investors it wanted $15 to $18 a share. It got $13.00.¹ Then, in its first day of trading, the stock slid to around $11 — the worst opening-day showing for any US listing raising more than $250 million since 2021.² The message from public markets was unambiguous: we have seen this movie. A private equity sponsor, a decade of tuck-in acquisitions, a mountain of floating-rate debt in a 5% interest-rate world, and a business model built on Medicaid and Medicare reimbursement. Pass.

Two and a half years later, on July 17, 2026, the same company was admitted to the S&P MidCap 400, replacing Chart Industries after Baker Hughes closed its acquisition of the industrial-gas firm.³ The shares changed hands north of $70 in the days that followed — against a 52-week low of roughly $19 — putting the equity value near $14 billion.⁴ From the IPO price, that is more than a fivefold return in under two and a half years, delivered not by a hyperscaler or a GLP-1 manufacturer but by a company whose core business is dispensing pills into nursing homes and sending nurses into the living rooms of frail 82-year-olds.

That gap — between what the market priced in January 2024 and what it pays today — is the entire subject of this story. It is tempting to describe it as a vindication. It is more useful to describe it as a repricing, and then to ask which parts of the repricing rest on durable economics and which rest on a one-time change in the company's financial architecture. Those are very different things, and conflating them is how investors get hurt at the top of a rerating.

Three threads run through the whole arc, and they are worth naming upfront because they recur in every section that follows.

The first is what management has called moving up the acuity ladder. BrightSpring began life in 1974 as Res-Care, a Louisville contractor running Job Corps centers for at-risk youth, and spent four decades as a provider of residential support for people with intellectual and developmental disabilities.⁵ That is honorable, socially necessary work. It is also, as a business, a structural trap: state-Medicaid funded, wage-driven, and chronically starved of margin. The company's transformation over the past decade has been a systematic migration from that world toward clinical services and pharmacy, where payment comes from Medicare and commercial payers, where scale actually buys something, and where the marginal patient is worth meaningfully more.

The second thread is neutrality as a competitive position. BrightSpring's specialty pharmacy business — Onco360 in oncology, CareMed in rare and orphan disease — competes against CVS Specialty, Accredo, and Optum Specialty. Those three are owned by the three dominant pharmacy benefit managers. Onco360 is not owned by a PBM, and that fact, more than any technology or cost advantage, is what drug manufacturers appear to be buying when they hand out limited-distribution rights. Whether that is a moat or merely a temporary market gap is one of the genuinely open questions in the story.

The third thread is the most financially consequential and the least glamorous: balance sheet arithmetic. On March 30, 2026, BrightSpring sold its founding business — the ResCare Community Living IDD operation, the direct lineal descendant of James Fornear's 1974 company — to Sevita for $835 million in cash.[^6] Roughly $811 million landed net of transaction costs, before about $100 million of taxes paid in the second quarter, and essentially all of it went to debt.⁶ Net leverage fell to 2.27x at the end of the first quarter of 2026, from 2.99x at the end of 2025 and something close to 6x before the IPO.⁷⁸

That last move deserves the emphasis it gets in this episode, because it is where the rerating physically comes from. When a levered equity deleverages, the equity value rises mechanically even if enterprise value does nothing at all. BrightSpring did both — enterprise value grew and the debt shrank — which is why the stock moved as violently as it did. The analytical task, then, is separating the leverage effect from the operating effect, and asking what is left to compound once the balance sheet story is over. Because it is over. Leverage cannot go from 6x to 2.3x twice.

To get there, we need to start where the money was worst.

↑ Back to Top

II. The Legacy of ResCare: James R. Fornear and the IDD Roots (1974–2016)

Picture Louisville, Kentucky in the mid-1970s. Not the Louisville of Churchill Downs and bourbon marketing, but the working city — a place where the federal government's Great Society programs still had money attached and where a man with the right résumé could turn a public mandate into a private business.

James R. Fornear had that résumé. He had run a Job Corps center for the US Department of Labor, the program created to give unemployed and disadvantaged young people vocational training and a path out. In 1974 he founded Res-Care as a private contractor to do that same work under government contract.⁵ The first real break came in 1976, when the company won the contract to operate the Whitney Young Job Corps Center in Shelby County, Kentucky. Two more centers followed in Crystal Springs and Gulfport, Mississippi.⁵

What happened next set the shape of the company for the following forty years. Around 1978, Res-Care opened the Higgins Learning Center near Morganfield, Kentucky, serving people with intellectual disabilities.⁵ It was a modest diversification at the time. It became the business.

Through the 1980s and 1990s, Res-Care built out what became one of the largest networks in the United States for residential and community support of individuals with intellectual and developmental disabilities — IDD in the industry's shorthand. Group homes. Intermediate care facilities. Day programs. Supported living arrangements where a direct support professional helps someone with a significant disability manage medication, meals, transportation, and the ordinary business of a life. It is intimate, essential, unglamorous work, and Res-Care did it at national scale.

The trouble is that the economics of that work are close to structurally fixed, and not in the operator's favor.

The payer problem. Almost all of it is funded by state Medicaid programs. That means fifty separate budget negotiations, each subject to the fiscal health of a single state, each vulnerable to a rate freeze in a recession year. A company can improve quality, win awards, cut waste — and still watch its revenue per client stay flat for four years because Springfield or Baton Rouge did not appropriate an increase. There is no pricing power in the ordinary commercial sense. There is only lobbying.

The labor problem. IDD residential care is not a business where technology substitutes for people. The service is the person. Direct support professionals are typically paid near the bottom of the wage scale, and turnover in the sector has routinely run above 50% annually — a figure that would be considered a crisis in almost any other industry and is treated as background weather in this one. Every dollar of minimum-wage inflation, every tightening of the local labor market, every Amazon warehouse opening within commuting distance of a group home lands directly on the cost line. And because the revenue line is set by a state legislature, the operator absorbs it.

The risk problem. Operating residences where vulnerable adults live twenty-four hours a day carries legal and regulatory exposure of a kind that does not scale gracefully. A single incident in a single home can trigger state investigation, licensure action, litigation, and headlines. Scale multiplies the number of homes; it does not reduce the per-home risk.

Put those three together and you have a business that can be large, durable, and socially valuable while generating single-digit operating margins and almost no operating leverage. Res-Care was, in effect, a labor-intensive government contractor wearing a healthcare costume.

The public market noticed. Res-Care spent years as a listed company with an unloved multiple, and in 2010 it was taken private by Onex Corporation, the Canadian private equity firm. Onex held it through the first half of the decade, running the standard playbook — professionalize, consolidate, tuck in adjacent providers — but the fundamental physics did not change. A roll-up of low-margin, wage-exposed, state-funded assets produces a bigger low-margin, wage-exposed, state-funded asset.

By 2016 the strategic question facing the board was not how to run IDD better. It was whether IDD alone could ever be the platform for a company worth several billion dollars. The honest answer was no. Which meant the company needed someone who was willing to say so out loud, and then to spend a decade acting on it.

↑ Back to Top

III. The Catalyst: Jon Rousseau and the Clinical Acuity Shift (2016–2018)

Jon Rousseau did not arrive at Res-Care in September 2016 as a social services lifer.⁹ He arrived as a capital allocator who had spent the previous three years running clinical businesses.

The biography matters here because it explains the strategy. Rousseau started at Morgan Stanley in investment banking from 1996 to 1998, then spent seven years in private equity at Friedman Fleischer & Lowe.⁹ That is the formative decade: a period spent looking at businesses as collections of cash flows with different qualities, learning to distinguish revenue that compounds from revenue that merely recurs. He then moved operational, joining Kindred Healthcare — also headquartered in Louisville — where from 2013 to 2016 he held a series of senior roles including president of Kindred Rehabilitation Services and president of the Care Management Division and Kindred at Home, the home health, hospice, home care, and home-based primary care platform.⁹

Kindred at Home is the critical experience. It gave him a working education in the economics of clinical care delivered in the patient's residence: how Medicare's home health reimbursement works, what an episode of care costs, how nurse productivity translates into margin, what it takes to run a hospice census. He came to Res-Care already knowing what a fifteen-percent-margin healthcare business looked like from the inside, and he came from a company whose home health assets would later be carved up among UnitedHealth, Humana, and — eventually — BrightSpring itself.

The strategic diagnosis he brought was blunt in its logic. A pure-play residential IDD business is not a platform for long-term equity compounding, because its revenue growth is capped by state appropriations and its costs are indexed to a tightening low-wage labor market. Over a long enough horizon, those two lines converge. You do not fix that with operational excellence. You fix it by changing what the company sells.

The "acuity ladder" is the frame worth holding onto, and it is simpler than it sounds. Think of healthcare services as a staircase. At the bottom are non-clinical supports: help with daily living, companionship, transportation, supervision. These are labor-heavy, low-skill, low-reimbursement. Climb a step and you get personal care with some clinical oversight. Climb again and you reach skilled home health — a nurse doing wound care, a physical therapist rehabilitating a hip after surgery. Higher still: hospice, home infusion, specialty pharmacy dispensing an oral oncolytic that costs $18,000 a month.

Each step up buys three things. Reimbursement shifts from state Medicaid toward federal Medicare and commercial payers, which means more standardized, more predictable, and generally better-funded rates. Margins improve, because the service requires licensure and clinical judgment that fewer competitors can supply. And barriers to entry rise, because you now need accreditation, pharmacy licensure, DEA registration, payer contracts, and clinical infrastructure — none of which a two-person startup assembles in a garage.

So from 2016 through 2018, the company began climbing. It acquired and expanded in home health, hospice, personal care with a clinical overlay, and specialized rehabilitation. It began building out the infrastructure — clinical quality measurement, referral relationships with hospitals and physician groups, payer contracting capability — that a clinical business requires and a group-home business does not.

And in 2018, the company made the change that told everyone what it intended: Res-Care rebranded as BrightSpring Health Services.⁹

It is easy to dismiss a rebrand as marketing. In this case it was closer to a public commitment device. "Res-Care" carried forty-four years of association with residential disability services — with state contracts, with survey deficiencies, with the social work sector. "BrightSpring Health Services" contained the word health. It signaled to hospital systems, to Medicare Advantage plans, to drug manufacturers, and eventually to public-market investors that this company intended to be evaluated as a healthcare provider, not a social services contractor. It also, quietly, made the eventual divestiture of the legacy business thinkable. You cannot easily sell the division your company is named after.

The strategic logic was coherent. But coherent strategy at a mid-sized levered company with modest cash generation is mostly a wish list. Climbing the acuity ladder required capital — a lot of it, deployed over years, against assets that were not cheap. Onex, having owned the business since 2010, was in the natural window for an exit rather than a re-investment cycle.

What BrightSpring needed was a new owner with a bigger balance sheet and a specific thesis about where healthcare was going. Two hundred miles away, a different Louisville-adjacent asset was already in play, and the firm buying it had exactly that thesis.

↑ Back to Top

IV. The KKR Masterplan: PharMerica, Walgreens, and Vertical Integration (2017–2019)

The first move was not BrightSpring at all. It was a pharmacy.

On December 7, 2017, PharMerica Corporation — a New York Stock Exchange–listed institutional pharmacy serving long-term care facilities across the country — ceased to be a public company. KKR, with an affiliate of Walgreens Boots Alliance as minority investor, acquired it in an all-cash transaction valued at approximately $1.4 billion including assumed and repaid debt, paying $29.25 per share.¹⁰[^12] PharMerica's stock stopped trading before the NYSE open the following morning.¹⁰

To understand why KKR wanted it, you need to understand what institutional long-term care pharmacy actually is, because it bears almost no resemblance to the CVS on the corner.

A nursing home with 120 beds might have residents taking, collectively, well over a thousand doses a day, across dozens of distinct medications, on strict schedules, with frequent changes. Someone has to fill those prescriptions, package them so that a nurse can administer the right pill to the right resident at the right hour without error, deliver them daily, handle emergency after-hours orders, manage controlled substances under DEA rules, reconcile the billing across Medicare Part D, Medicaid, and private pay, and provide a consultant pharmacist who reviews each resident's regimen for interactions and inappropriate prescribing — a service Medicare regulation requires. That is not retail. It is closer to industrial logistics with a clinical license attached.

The result is a business with two attractive properties. First, it is genuinely sticky. A facility that has integrated its electronic medication administration record with a pharmacy's system, trained its nurses on that pharmacy's packaging, and built its workflow around that pharmacy's delivery schedule does not switch casually. The switching cost is not a contract penalty; it is operational chaos for weeks. Second, it is a scale business on the buy side. Drug procurement economics reward volume, and a national dispenser buys better than a regional one.

What it is not is a high-margin business. Pharmacy revenue is mostly the pass-through cost of drugs. That structural fact will matter enormously later.

Fifteen months after the PharMerica close, KKR completed the other half. On March 5, 2019, it closed the acquisition of BrightSpring from Onex for approximately $1.32 billion, again with Walgreens Boots Alliance as a minority investor, and immediately merged BrightSpring with PharMerica under a single parent.¹¹¹² The combined company served over 300,000 people daily across 47 states, Puerto Rico, and Canada, with roughly $4.5 billion in combined revenue.¹¹

The thesis KKR was underwriting is worth stating carefully, because it is the intellectual core of the company and it is also the part most often repeated uncritically.

The premise: a small fraction of the population — medically complex, mostly elderly, often frail — accounts for a wildly disproportionate share of US healthcare spending. A meaningful driver of that spending is polypharmacy. An 84-year-old with heart failure, diabetes, atrial fibrillation, and osteoarthritis may be on twelve to fifteen medications prescribed by four different physicians who have never spoken to one another. The interactions between those drugs cause dizziness, cause falls, cause confusion, cause a fall down the stairs, cause a hip fracture, cause a hospitalization, cause a skilled nursing stay — a cascade that costs the system tens of thousands of dollars and costs the patient, often, their independence permanently.

The proposition: if the same organization dispenses the drugs and sends the nurse into the home, it can see the whole picture. The pharmacist notices a new prescription that interacts badly with an existing one. The home health nurse reports that the patient seems unsteady since the dose change. Someone connects those two facts before the fall rather than after it. BrightSpring built programs around exactly this — CCRx and Continue Care — pairing pharmacist medication review with clinical field staff.

The commercial payoff: sell a lower total cost of care to Medicare Advantage plans, managed Medicaid organizations, and accountable care entities. In a fee-for-service world, preventing a hospitalization destroys revenue. In a value-based world, where a plan is paid a fixed amount per member and keeps the difference, preventing a hospitalization is the whole business model. A vendor who can credibly demonstrate reduced readmissions becomes a partner rather than a cost line.

That is an elegant thesis. Here is the honest caveat an independent analyst should attach to it: the cross-selling synergy between pharmacy and provider services has always been more compelling in a deck than in the reported numbers. The two segments serve overlapping but far from identical populations, they contract with payers separately, and BrightSpring has never published a clean disclosure isolating the incremental revenue or margin attributable to integrated pharmacy-plus-provider relationships. The company's actual growth over the following seven years came overwhelmingly from each business growing well on its own — pharmacy through specialty drug volume, provider through home health census — rather than from a demonstrable integration premium.

That does not make the merger a mistake. Owning two good businesses is fine. But an investor should be clear-eyed that "integrated senior care at home" functions today more as a strategic narrative and a customer-facing positioning than as a quantified financial mechanism. The proof, if it comes, will show up in payer contracts explicitly priced on total cost of care — and those remain a small share of the revenue base.

What KKR had built by mid-2019 was a $4.5 billion revenue platform combining a sticky, scale-advantaged, low-margin pharmacy with a growing, higher-margin clinical services business and a legacy IDD operation attached to the bottom. What it had also built was a great deal of debt.

↑ Back to Top

V. The Private Equity Era: Roll-Ups, Leverage, and the IPO Skepticism (2019–2024)

Every leveraged buyout is a bet that the cash flows arrive before the interest payments become unbearable. KKR made that bet twice, stacked the two companies on top of each other, and then ran into a global pandemic in the business of caring for elderly people in congregate settings.

The financing was aggressive by design. The combined platform carried net debt in excess of $3 billion, with leverage that pushed toward six times adjusted EBITDA and beyond — the standard architecture for a sponsor-owned healthcare services roll-up in the late-cycle credit environment of 2019, when covenant-lite term loans were abundant and the base rate was near zero. At that leverage level, with rates where they were, the interest burden was manageable. The plan was to grow EBITDA, delever naturally, and exit within five years.

Then two things happened that were not in the model. COVID-19 hit long-term care facilities harder than any other setting in America, disrupting census, spiking labor costs, and reordering the entire referral ecosystem. And in 2022 the Federal Reserve began raising rates at the fastest pace in four decades, converting a floating-rate capital structure from a cheap accelerant into an expensive anchor.

Through all of it, the M&A engine kept running. Between 2019 and 2023 the company completed dozens of acquisitions — small pharmacy operators, home health branches, hospice agencies, infusion sites. This is where the private equity craft is most visible, and it is worth being precise about the mechanic, because "roll-up" is often used as an insult when it describes something genuinely value-creating.

The arbitrage works like this. Public and large private healthcare services platforms trade at a multiple of EBITDA set by scale, diversification, and growth. During the pandemic-era home health boom, publicly traded pure-plays like LHC Group and Amedisys commanded valuations in the high teens as strategic buyers — UnitedHealth's Optum most prominently — competed for national platforms. A single-market home health agency with $8 million of revenue and one owner nearing retirement does not trade at that multiple. It trades at six to eight times EBITDA, because it has key-person risk, no payer negotiating leverage, no scale in back-office cost, and a limited buyer universe.

Buy at seven, fold into a platform valued at twelve or fifteen, strip out duplicated administrative cost, and the spread is created on the day of closing. Do it forty times and the compounding is substantial. The discipline test is whether the acquirer resists the temptation to buy the expensive platform assets when everyone else is bidding — and on that test, KKR's entry multiples on both BrightSpring and PharMerica, at roughly ten to eleven times forward EBITDA, look conservative against what strategics were paying for home health at the peak.

But there is a limit to how long a company can stay in that structure, and by 2023 KKR had held the asset for four years with an exit window that had slammed shut in 2022 and reopened only partially. The IPO was filed, pulled, and revived.¹³

Which brings us back to that January 2024 morning.

The pitch: a $9 billion revenue healthcare platform with two attractive end markets and a demonstrated acquisition capability. The market's response was a list of objections, and they were not unreasonable ones.

Objection one: leverage. Entering the public market at roughly six times net debt to EBITDA, with a substantial floating-rate component, at a moment when the effective federal funds rate exceeded 5%, meant a very large share of EBITDA was going to lenders rather than shareholders. Every 100 basis points of rate movement was worth real money.

Objection two: sponsor overhang. KKR would retain control after the offering. Public shareholders would be minority partners in a company whose largest holder had a defined intention to sell over time — a persistent supply overhang and a governance structure in which minority interests are structurally secondary.

Objection three: margin quality. At the consolidated level, BrightSpring's EBITDA margin was low single digits, because pharmacy revenue is mostly drug cost passing through. Investors accustomed to screening on margin saw a number that looked like a distributor and a valuation ask that looked like a services company.

Objection four: reimbursement risk. Roughly half the revenue base traced to government payers whose rates are set by rulemaking, not negotiation.

So the deal priced at $13.00, raising $693 million on 53.3 million shares, alongside $400 million of tangible equity units sold at $50 each carrying a 6.75% coupon — about $1.1 billion of total proceeds.¹² Tangible equity units are a hybrid: part prepaid forward purchase contract on the stock, part senior amortizing note. They exist to raise capital from investors who want equity upside with a contractual cash return, and their presence in a deal is itself a signal — a company confident of demand for straight equity does not usually need them.

The proceeds went to debt.¹³ Not to acquisitions, not to a founder's secondary, not to a balance sheet cushion. To debt.

That allocation decision, repeated consistently over the following two years, is the single most important behavioral fact about this management team. Companies say they will delever all the time. The ones that actually route every incremental dollar to the credit agreement rather than to empire-building are rarer than the transcripts suggest. Whether that reflected genuine discipline or simply the absence of alternatives at a $13 share price is a fair question — a levered company with an unloved stock has few good options besides paying down debt. But the pattern held even after the stock rerated, which is the harder test.

Meanwhile, inside the company, a business the public market had barely priced was compounding at a rate almost nobody had modeled.

↑ Back to Top

VI. Smashed Expectations: The Explosion of Onco360 and Specialty Pharmacy

Here is the mispricing in one sentence: investors bought BrightSpring as a home nursing company with a pharmacy attached, and what they actually owned was a specialty pharmacy with a home nursing company attached.

The pharmacy business the market underweighted has three distinct pieces. Institutional long-term care dispensing — the PharMerica legacy. Home infusion, operating as Amerita, delivering IV therapies in the patient's residence. And specialty pharmacy: Onco360 in oncology, CareMed in rare and orphan disease.

Onco360's origins run back to December 2013, when PharMerica took a significant minority stake in the oncology pharmacy with an option to acquire the remainder over subsequent years, explicitly to build a national oncology pharmacy and care management platform.¹⁴ At the time it was a sensible adjacency. It became something much larger.

To see why, you need to understand what a limited distribution drug is, because it is the load-bearing concept in this section.

When a pharmaceutical company launches a conventional medication, it wants it everywhere — every pharmacy, every wholesaler, maximum access. When it launches a complex specialty therapy — a targeted oral oncolytic, a cell therapy, a treatment for a disease affecting four thousand people nationwide — it wants the opposite. It wants a small number of pharmacies that can be trained deeply on the product, that can manage a REMS safety program, that can chase down prior authorizations with insurers, that can enroll patients in copay assistance so a $20,000-a-month therapy does not go unfilled, that can call the patient weekly to manage side effects so they stay on the drug, and that can report structured data back to the manufacturer on adherence and outcomes.

So the manufacturer restricts distribution to a handful of named pharmacies. That is a limited distribution drug. For the pharmacy that wins the designation, it is a durable annuity: every patient in the United States prescribed that therapy flows through a very small number of doors, for as long as the drug is on the market. It is close to a textbook example of what Hamilton Helmer calls a cornered resource — a preferential access to a valuable asset that competitors cannot replicate at any price, because the decision rests with a third party.

Now the strategic question: who does the manufacturer choose?

The three largest specialty pharmacies in America are CVS Specialty, Accredo, and Optum Specialty. They are owned, respectively, by CVS Health (which owns Caremark), Cigna's Evernorth (which owns Express Scripts), and UnitedHealth (which owns OptumRx). In other words, the largest specialty dispensers are subsidiaries of the largest pharmacy benefit managers — the entities that negotiate rebates with manufacturers, build formularies, and decide whether a drug is covered, at what tier, with what patient cost-sharing.

For a drug manufacturer, that is an awkward relationship. Your distribution partner's corporate parent is simultaneously your toughest price negotiator, and it has visibility into your patient-level data. If a PBM's formulary decisions favor a competing product, the same organization is dispensing yours.

Onco360's pitch is that it has none of those conflicts. It is not owned by a PBM. It has no formulary to protect and no rebate negotiation running in parallel. It is, in the industry's language, an independent — but at national scale, which is the unusual part. Independence is common among small pharmacies; independence combined with the operational infrastructure to support a national product launch is rare.

The evidence that this positioning works is in the LDD count. On the Q1 2026 earnings call, management reported adding four exclusive or ultra-narrow limited distribution drugs during the quarter, bringing the total portfolio to 153.¹⁵ That is a portfolio built one manufacturer decision at a time over more than a decade, and each addition is a small, permanent annuity layered on the previous ones.

The financial consequences show up in a metric that rewards close reading. For full-year 2025, BrightSpring dispensed 43.4 million prescriptions — up about 4% year over year. Pharmacy Solutions revenue was $11.4 billion, up 31%.⁸ Those two numbers can only be reconciled one way: revenue per script rose 26%, to $263.93.⁸ By the first quarter of 2026, revenue per script reached $295.56, up 27% year over year.¹⁶

That is the entire specialty story compressed into one ratio. The company is not dispensing many more pills. It is dispensing dramatically more expensive pills — high-cost oncology and rare-disease therapies replacing ordinary maintenance medications in the mix. Management confirmed the mechanism on the Q1 call, describing specialty and infusion script growth of roughly 30% year over year, with specialty running ahead of infusion's mid-teens pace.¹⁵

There is a second, less-discussed piece of the specialty franchise that deserves attention. Alongside dispensing, BrightSpring runs fee-for-service programs — patient support hubs operated on behalf of manufacturers, handling benefit verification, financial assistance, and adherence support. Management said on the Q1 2026 call that this business comprised 31 hub programs growing 40–50% year over year and was becoming increasingly material to profitability, while remaining below a majority contribution.¹⁵

That is strategically more interesting than the dispensing growth. Hub services carry no drug cost. They are a fee for labor and clinical infrastructure, which means the margin profile is entirely different — closer to a specialty services business than a distributor. If that mix continues to grow at 40–50%, it changes the character of the pharmacy segment over time. It is also a business built on the same asset as the LDD portfolio: manufacturer trust. The same neutrality argument that wins a distribution designation wins a hub contract.

Now the falsification test, because the bull case here is not unconditional. What would break it?

The most direct threat is payer-driven channel steering. A PBM that decides its own specialty pharmacy will dispense a given therapy can, through network design, route patients away from Onco360 regardless of what the manufacturer prefers. The manufacturer chooses who may dispense; the payer influences who does. Analysts pressed management on exactly these PBM dynamics on the Q1 2026 call, and the response emphasized limited exposure to private-label biosimilars and "healthy partnerships" across the value chain.¹⁵ That is a reassuring answer rather than a quantified one, and an investor should note the distinction. There is no public disclosure of what share of Onco360 volume sits in networks controlled by the three integrated PBMs.

The second threat is generic and biosimilar erosion. An LDD annuity lasts exactly as long as the drug's exclusivity. When a blockbuster oncology therapy loses protection, the limited distribution structure typically collapses and the revenue goes with it. The portfolio must be continuously replenished — four new LDDs a quarter is not a nice-to-have, it is the maintenance requirement.

The third is reimbursement compression. Specialty dispensing margin is a spread over acquisition cost, and that spread has been under pressure across the industry for a decade. Volume growth can mask rate compression for a long time, and then stop masking it very suddenly.

So the specialty business is genuinely valuable and genuinely growing, with a defensible structural position. It is not, however, insulated from the two organizations that sit on either side of it — manufacturers above and PBMs beside. That is a real edge with real dependencies, which is a more useful way to hold it than as a moat.

While the market was slowly discovering all of this, management was preparing a move that would force the issue.

↑ Back to Top

VII. The Grand Divestiture: Selling ResCare Community Living to Sevita

There is a particular kind of corporate decision that only makes sense if you are willing to be unsentimental about your own history. On March 30, 2026, BrightSpring completed the sale of its community living services, home and community-based waiver programs, and intermediate care facilities to Sevita for aggregate cash consideration of $835.0 million.[^6]⁶

That business was Res-Care. Not a division of it — the operating heart of what James Fornear had built starting in 1974 and what had carried the company's name until 2018. Fifty-two years after the founding, the company sold the founding business and kept the pharmacy.

The financial mechanics were straightforward and the effects were not subtle. Net cash proceeds before tax came to approximately $811 million, with roughly $100 million of taxes payable in the second quarter of 2026. The transaction produced a $31.2 million after-tax gain recorded in discontinued operations.⁶ The cash went to debt, and net debt landed around $1.7 billion at quarter end.⁶

Leverage tells the story most cleanly. At the end of 2025 the ratio stood at 2.99x, itself down sharply from 4.16x a year earlier.⁸ By March 31, 2026 it was 2.27x, against pro forma leverage of 2.60x at December 31, 2025.¹⁶ From something near six times at the time of the IPO to roughly two and a quarter times in a bit over two years is not incremental improvement. It is a different company from a credit perspective.

But the transaction did not close quietly, and the regulatory chapter is instructive about the industry structure.

The FTC problem. BrightSpring and Sevita were the two largest providers of IDD services in the United States. In January 2026, the Federal Trade Commission filed a complaint alleging that combining them would harm competition in the provision of care to people with intellectual and developmental disabilities in specific local markets.[^19]

Consider what that allegation implies. In many localities, there are only one or two organizations capable of operating an intermediate care facility for individuals with profound disabilities. The "customer" — a state Medicaid agency placing a resident — often has no realistic alternative. The individuals receiving the care cannot meaningfully shop. Competition, such as it is, exists between a small number of licensed operators, and removing one of two can leave a genuine monopoly over an exceptionally vulnerable population.

The remedy was structural. Sevita was required to divest 128 intermediate care facilities and related assets, including day-training programs, located in Indiana, Louisiana, and Texas, to Dungarvin Group Inc., an established ICF operator.¹⁷¹⁸ The consent order also obligated Sevita to help Dungarvin obtain the licenses, permits, authorizations, and certifications necessary to operate the divested facilities — a detail that matters, because in this sector a facility without state licensure is not an asset, it is a liability.¹⁷ The FTC finalized the consent order in June 2026.¹⁷

The regulatory episode carried an unintended message about the asset BrightSpring was selling. An antitrust complaint is, in effect, an official statement that the acquirer would hold too much of a market. That is the profile of a mature, consolidated, geographically fragmented sector where the remaining growth comes from taking share rather than expanding the pie — precisely the characteristics that make an asset a good thing to sell and a hard thing to compound.

What the sale actually did to the equity. Three things, and it is worth separating them.

First, the mechanical deleveraging. Applying $811 million of pre-tax proceeds to debt directly transfers enterprise value from creditors to shareholders. At a constant enterprise value, that alone lifts the equity.

Second, the mix shift. Removing a low-margin, wage-exposed, Medicaid-dependent business raises the consolidated margin and growth profile of what remains. The continuing business is pharmacy plus clinical provider services — higher growth, better-funded payers, less exposure to state budget cycles.

Third, and most powerfully, the narrative reclassification. Before the sale, BrightSpring screened as a levered, Medicaid-exposed, PE-controlled roll-up — a category that carries a structural discount in public markets regardless of underlying quality. After the sale, it screened as a deleveraged specialty pharmacy and clinical home health company. The cash flows changed somewhat. The category changed entirely. And in equity markets, category determines the multiple.

The stock's path from $13.00 to above $70 reflects all three effects operating together, compounded by earnings growth that ran well ahead of expectations. Q1 2026 revenue of $3.614 billion was up 25.6% year over year, adjusted EBITDA of $190 million up 44.8%, and reported EPS of $0.39 against a consensus near $0.16 — a beat large enough to move the shares more than 11% premarket.¹⁶¹⁵

Here is the skeptic's note, and it should be held alongside the celebration. Two of the three drivers of this rerating are non-repeatable. The company can only sell its founding business once. Leverage can only fall from six times to two and a quarter times once. The category can only be reclassified once. From roughly 2.3x leverage and a mid-cap multiple, the equity now has to compound on operating performance alone — and the market has already paid for a good deal of that performance in advance.

Which makes the question of what the remaining business actually earns, and how defensible those earnings are, the only question left.

↑ Back to Top

VIII. Segment Economics & Competitive Benchmarking

Strip away the narrative and BrightSpring's continuing operations resolve into a genuinely odd shape — two businesses whose contributions to revenue and to profit are almost inverted.

The revenue picture. For full-year 2025, total revenue was $12.911 billion, up 28.2%. Pharmacy Solutions accounted for $11.446 billion of that — roughly 89% — growing 31%. Provider Services contributed $1.465 billion, about 11%, growing 11%.⁸

The profit picture. Pharmacy Solutions generated $544 million of segment EBITDA, up 38%. Provider Services generated $233 million, up 13%.⁸ So pharmacy delivered about 70% of combined segment EBITDA on 89% of revenue, and provider delivered 30% on 11%. Net of corporate overhead, total company adjusted EBITDA was $618 million, up 34.2% from $460 million in 2024.⁸

The margin implication follows directly. Pharmacy runs at roughly 4.8% segment EBITDA margin; provider runs at close to 16%.

Those two numbers describe two completely different businesses, and the most common analytical error with BrightSpring is judging them by the same yardstick.

Why pharmacy's margin is low and why that is fine. When Onco360 dispenses a therapy costing $18,000, that $18,000 flows through revenue. The company's economics are the spread over acquisition cost plus dispensing and service fees. A 4.8% margin on $11.4 billion produces $544 million of EBITDA — which is a large absolute number, and it is what matters. Judging this business on margin percentage is like judging a wholesale distributor on the same basis as a software company: the ratio is meaningless without the asset base underneath it. The relevant questions are return on invested capital, working capital intensity, and whether the spread itself is stable.

Working capital is the underappreciated risk in this model. High-cost drugs must be purchased before payers reimburse. Rapid growth in a business like this consumes cash even when it is highly profitable, because inventory and receivables scale with revenue. That makes the 2025 operating cash flow figure genuinely notable: $490 million, against just $24 million in 2024.⁸ A twentyfold increase in operating cash flow in a year when revenue grew 28% indicates the company converted growth into cash rather than into receivables — the single best evidence available that the specialty ramp is real rather than an accounting artifact of aggressive revenue recognition.

Why provider's margin is high and why it is capacity-constrained. Home health, hospice, and rehabilitation are labor businesses with clinical licensure requirements. A 16% margin reflects genuine service value. But growth is bounded by nurse and therapist availability, which is why this segment grew 11% while pharmacy grew 31%. You cannot hire a home health nurse the way you can order more inventory.

Which makes the 2025 acquisition of 107 home health and hospice branches from the Amedisys and LHC divestitures the most strategically interesting deal in years.⁸ These branches came onto the market because UnitedHealth's acquisition of Amedisys required antitrust divestitures — the same regulatory dynamic that shaped BrightSpring's own exit from IDD, running in the opposite direction. BrightSpring acquired licensed, staffed, operating clinical capacity that could not have been built organically at any reasonable speed.

Early integration evidence has been encouraging. Management reported that in Q1 2026 the acquired branches contributed approximately $79 million of revenue and about $9 million of adjusted EBITDA, tracking toward a full-year contribution of roughly $30 million, with a "step-up in admissions" under BrightSpring management.¹⁵⁸ The census data corroborates: home health average daily census reached 46,066 in Q1 2026, up 52% year over year — a figure dominated by the acquisition but consistent with the acquired branches operating rather than idling.¹⁶ For context, full-year 2025 average daily census was 31,135, up 9% organically.⁸

A cautionary note is warranted: one quarter of integration data is thin evidence. Divested branches are frequently the ones the seller was least sorry to lose, and clinical staff attrition after an ownership change often shows up in quarters two through four rather than quarter one. The full-year outcome against the $30 million target is a genuine test of the M&A capability the entire roll-up thesis rests on.

The competitive war-game. In institutional long-term care pharmacy, the incumbent to beat is CVS's Omnicare. PharMerica has taken share over an extended period, and the reason is more prosaic than strategic brilliance: this is a service execution business. Facilities switch pharmacies when deliveries arrive late, when emergency orders are mishandled, when billing errors force nursing staff to spend hours on the phone. A dedicated institutional pharmacy operator whose entire organization is oriented around that customer tends to out-execute a division inside a sprawling retail-and-insurance conglomerate with competing priorities. Mid-sized competitors including Remedi SeniorCare and PharmScript occupy the regional tier below.

In clinical home health and hospice, the landscape reordered dramatically. LHC Group went to Optum. Amedisys followed into the UnitedHealth orbit, shedding branches on the way. Enhabit was spun out of Encompass Health. Pennant Group operates a decentralized model. The structural feature that matters: home health is intensely local. Referrals come from hospital discharge planners and physicians in a specific city, and a national brand carries limited weight with a discharge planner who cares about which agency can accept a patient tomorrow. That fragmentation limits winner-take-all dynamics — but it also means every local market is winnable, which is exactly the condition under which a disciplined acquirer with a lower cost of capital can keep compounding.

The two segments, then, present opposite risk profiles: pharmacy has scale and growth but thin spreads and powerful counterparties; provider has attractive margins but capacity limits and administered pricing. Understanding what each contributes is the prerequisite for the harder question — what generalizable lessons this transformation actually teaches.

↑ Back to Top

IX. Playbook: Business & Investing Lessons

Every good business story leaves behind a set of transferable principles. BrightSpring's are unusually clean, partly because the transformation was executed slowly enough to observe each step, and partly because the counterfactual — the company that stayed in IDD — is visible in the sector's other operators.

Lesson 1: A legacy business is a starting position, not a destiny — but escaping it takes a decade.

The acuity ladder pivot worked. But note the timeline. Rousseau arrived in September 2016. The rebrand came in 2018. The pharmacy merger closed in 2019. The IPO was 2024. The divestiture of the legacy business completed in 2026. That is nearly ten years from strategic diagnosis to full execution, spanning a pandemic, a rate cycle, and an ownership change.

The transferable insight is about sequencing. The company did not sell the IDD business first and then figure out what to become. It built the replacement business first — acquiring clinical capacity, merging with pharmacy, establishing the specialty franchise — and only sold the legacy operation once the new identity was independently viable and once a buyer existed who valued the asset more than the seller did. Selling first would have left a smaller company with cash and no strategy, and would have crystallized the sale at the bottom of the valuation cycle rather than into a consolidating market.

For investors, the lesson is patience combined with milestone discipline: a transformation thesis should be underwritten against observable checkpoints — segment mix, margin trajectory, capital allocation — not against management's stated intention.

Lesson 2: Vertical integration must solve a real problem for a paying party, and you should demand evidence that it does.

The polypharmacy thesis is the intellectual justification for combining pharmacy and clinical services. It is a good thesis. But as noted earlier, BrightSpring's growth has come substantially from each segment succeeding independently rather than from a quantified integration premium.

That yields a genuinely useful heuristic. When evaluating any vertical integration story, ask: who writes a check specifically because these two things are combined? If the answer is "payers pay us more under value-based contracts," ask what share of revenue those contracts represent. If the answer is "it makes us a better partner," that is positioning, not economics. Positioning has value — it wins referrals and contract renewals — but it should not be capitalized at a synergy multiple.

Lesson 3: In a high-rate environment, deleveraging is the highest-return capital allocation available to a levered equity — and the market pays twice for it.

This is the most financially instructive lesson. Consider what BrightSpring's management did with every significant cash inflow from 2024 through 2026: IPO proceeds to debt; tangible equity unit proceeds to debt; divestiture proceeds to debt.

The return on that allocation was extraordinary, and it came in two forms. The direct form is arithmetic — retiring debt at a high effective cost transfers value to equity holders at a rate few operating investments can match. The indirect form is the multiple. Highly levered equities trade at depressed multiples because financial risk compounds operating risk; as leverage normalizes, the discount compresses. Shareholders capture both the value transfer and the rerating.

The corollary is the discipline test that comes after. A company at 2.27x leverage with strong cash generation has a great deal of optionality, and optionality is where capital allocation discipline usually dies. Management has signaled a target in the "mid-2s" with flexibility for disciplined M&A, and the CFO indicated they would remain active in evaluating options for the existing term loan.¹⁵ Watching whether leverage stays near that target — or drifts back up to fund acquisitions at rising multiples now that the stock is expensive — is the single most informative behavioral signal available over the next several years.

Lesson 4: In an industry organized around vertical giants, scaled independence is a product.

Onco360's advantage does not come from better technology or lower cost. It comes from the absence of a conflict that every large competitor structurally possesses. That is a strategic position available only in industries where consolidation has gone far enough that neutrality itself becomes scarce.

The generalizable version: when an industry vertically integrates, look for the function where integration creates a conflict of interest for a powerful third party. That third party will pay — in access, in preference, in contract terms — for a credible independent alternative. The catch, and it is significant, is that such positions are contingent on someone else's structure. If PBM ownership of specialty pharmacy were unwound by regulation, or if manufacturers concluded that scale mattered more than neutrality, the advantage would erode without BrightSpring doing anything wrong.

Which is the right frame for the final section: not whether the story so far was impressive — it plainly was — but what the structural position actually supports from here.

↑ Back to Top

X. Analysis: Porter's 5 Forces, Helmer's 7 Powers, and the Bull vs. Bear Case

Strip away the narrative arc and ask the cold question a skeptical investor would ask at $70 a share: what, precisely, prevents this business from being competed down to a commodity return?

Helmer's 7 Powers applied

Cornered Resource — the strongest claim, with a maintenance requirement. The 153 limited distribution drug agreements are the clearest genuine power in the portfolio.¹⁵ A competitor cannot replicate them through investment, because the decision belongs to manufacturers. But this is a wasting asset requiring continuous replenishment as drugs go generic. The power is real; it is a treadmill rather than a wall.

Scale Economies — real but bounded. National procurement volume in pharmacy buys better acquisition economics than a regional independent can achieve, and central back-office cost spreads across a larger base. But BrightSpring's scale is dwarfed by CVS, Cigna, and UnitedHealth. It has enough scale to beat regional operators; not enough to dictate terms to anyone above it. In Provider Services, scale economies are weak — home health is delivered locally by people who drive to houses, and a national network does not make a nurse visit cheaper.

Switching Costs — genuine in institutional pharmacy. The workflow integration between PharMerica and a long-term care facility — packaging conventions, delivery schedules, eMAR integration, consultant pharmacist relationships — creates real operational friction to switching. Not contractual lock-in; something more durable, because the cost of switching is borne by the nursing staff who would have to relearn their medication routine. In home health, switching costs are essentially nil: a discharge planner can refer to a different agency tomorrow.

Absent powers, and this matters. There is no meaningful network economy — an additional patient does not make the service better for other patients. There is little branding power in the consumer sense; patients do not choose their home health agency by brand. There is no counter-positioning — competitors could copy the model if the economics justified it. And process power, the accumulated operational know-how that resists imitation, is plausible but unproven from outside.

Three powers out of seven, two of them qualified. That is a real but not overwhelming structural position.

Porter's Five Forces

Buyer power: high, and this is the dominant force. Medicare rates are set by CMS rulemaking. Medicaid rates by state legislatures. Commercial and Medicare Advantage rates by large, consolidated payers. In no case does BrightSpring set its own price for the majority of its revenue. This is the fundamental ceiling on the business and no amount of operational excellence removes it.

Supplier power: high in specialty, mitigated by structure. Pharmaceutical manufacturers of breakthrough oncology therapies hold enormous power — they set the drug cost, they grant or withdraw distribution rights. Onco360's neutrality converts a purely adversarial relationship into a partly cooperative one, but it does not reverse the balance.

Rivalry: bifurcated. Intense in specialty pharmacy against three vertically integrated giants. More moderate in clinical home health, where geographic fragmentation means most competition is with a handful of local agencies rather than a national adversary.

Threat of substitutes: low, and structurally favorable. Home-based care is the substitute — the lower-cost alternative to skilled nursing facilities and hospitals that patients overwhelmingly prefer. The direction of substitution runs toward BrightSpring's setting, not away from it.

Barriers to entry: high. State pharmacy licensure, DEA registration, accreditation, Medicare certification, payer contracts, manufacturer relationships, and physical clinical infrastructure. This is not a market a well-funded startup enters quickly.

The bull case, tested

Demographics. Roughly ten thousand Americans turn 65 every day, and the medically complex elderly are the core customer. This is the most reliable element of the thesis because demographics are the one variable that does not surprise. The caveat: demographic tailwinds accrue to the entire sector, not to BrightSpring specifically. They raise the tide; they do not confer share.

Specialty oncology growth. Oncology drug spending has grown faster than overall drug spending for years, and the pipeline is weighted toward targeted therapies that require exactly the distribution model Onco360 operates. Evidenced by revenue-per-script expansion and LDD portfolio growth. Dependent on continued manufacturer preference and PBM network access.

Balance sheet. At 2.27x, financial risk is materially reduced and the company has capacity for M&A.¹⁶ Evidenced and verified. Also, as noted, largely spent as a source of further rerating.

Value-based care. Genuine directional tailwind, weakest evidentiary support. The company has not disclosed metrics isolating value-based contract revenue or demonstrated readmission reduction economics.

Execution record. Management has raised full-year 2026 guidance to revenue of $14.73–15.23 billion and adjusted EBITDA of $795–825 million, up from the $14.45–15.00 billion and $760–790 million provided at year-end.¹⁶⁸ A guidance raise one quarter into the year, following a pattern of raises through 2024 and 2025, is meaningful evidence of forecasting discipline — though it also establishes an expectation that a single miss would puncture.

The bear case, taken seriously

Reimbursement is a policy variable, not a market outcome. CMS finalized the CY2026 Home Health Prospective Payment System rule with an estimated aggregate reduction of 1.3%, or approximately $220 million across all home health agencies, versus 2025.¹⁹ The detail matters: CMS had proposed a 6.4% reduction and finalized a permanent behavioral adjustment of −1.023% plus a −3.0% temporary adjustment, after commenters argued that post-2022 behavior change reflected factors unrelated to PDGM implementation.¹⁹ So the outcome was far better than proposed — but the proposal itself is the signal. CMS believes home health has been overpaid under PDGM and has been steadily working that back. Each annual rulemaking is a live risk to the highest-margin segment, and the trajectory has been negative.

The IRA headwind is large and quantified. Management disclosed that the Inflation Reduction Act's impact on home and community pharmacy cost roughly $50 million of revenue in Q1 2026, with approximately $45 million expected in each remaining quarter — on the order of $175 million for the year.¹⁵ The company has offset this through procurement initiatives and operational automation while still expanding margins.¹⁵ That is a credible operational response. But it is a headwind that recurs, driven by federal drug pricing policy the company cannot influence, and brand-to-generic conversion compounds it.

Labor is the binding constraint on the good segment. Nursing and aide shortages cap how fast Provider Services can grow regardless of demand. Provider Services grew 11% in 2025 against pharmacy's 31%.⁸ The margin-rich segment is the growth-constrained one.

The activist's questions. A skeptical investor at current levels would push on several things. Multiple justification: the equity now trades at a valuation that requires sustained operating growth, with the deleveraging catalyst spent. Disclosure granularity: BrightSpring reports two segments while operating at least five materially different businesses — institutional pharmacy, specialty pharmacy, home infusion, home health/hospice, and rehab/personal care — with very different growth and margin profiles. An investor cannot independently verify how much of Pharmacy Solutions EBITDA comes from Onco360 versus PharMerica, which is precisely the disclosure that would let the market underwrite the thesis rather than trust it. Acquisition accounting: a company completing dozens of acquisitions carries substantial goodwill and intangibles, and adjusted EBITDA excludes acquisition and integration costs that recur year after year in a serial acquirer. The gap between adjusted EBITDA and free cash flow deserves ongoing scrutiny. Sponsor overhang: KKR's remaining position and its eventual disposition remain a supply consideration. Concentration in one growth engine: if specialty pharmacy is the primary driver, the equity is substantially a bet on one franchise's continued manufacturer access.

Management credibility

The behavioral record over the past two and a half years is genuinely strong, and it is worth being specific about why rather than simply asserting it.

The narrative has been consistent. The strategy articulated at the IPO — grow pharmacy volume, expand clinical services, delever, add tuck-in acquisitions — is the strategy described on the Q1 2026 call, using the same three-driver framing of volume growth, operational efficiency, and accretive M&A.¹⁵ Serial strategy revision is one of the most reliable warning signs in a levered roll-up, and it has been absent here.

Guidance has been raised repeatedly rather than cut, and capital allocation has matched stated intent. When the divestiture proceeds arrived, they went where management said they would go.

Compensation is heavily equity-weighted, aligning management with share price performance; the specific structure and amounts are disclosed annually in the company's proxy statement.²⁰ That alignment cuts both ways: it rewards value creation and it creates incentive to sustain a high multiple, which is worth remembering when assessing disclosure choices and the framing of adjusted metrics.

The fair criticisms are about transparency rather than integrity: segment reporting that obscures the mix within Pharmacy Solutions, and qualitative rather than quantified answers on PBM channel exposure.

The KPIs that actually matter

Three metrics, and only three, capture whether this thesis is intact.

Revenue per prescription in Pharmacy Solutions. This single ratio is the cleanest proxy for specialty mix shift. It rose to $263.93 for full-year 2025 and $295.56 in Q1 2026.⁸¹⁶ Continued expansion means the high-value specialty mix is still growing. Deceleration or reversal signals either lost LDD access, PBM channel steering, or generic erosion — the three things that would break the pharmacy story. Watch it every quarter.

Home Health average daily census. The volume engine of the high-margin segment. Full-year 2025 averaged 31,135; Q1 2026 reached 46,066, reflecting the acquired branches.⁸¹⁶ The critical read is the organic trajectory once the Amedisys and LHC branches annualize into the base, because that separates genuine clinical demand capture from acquisition arithmetic.

Net leverage ratio. At 2.27x, it is both the record of past discipline and the forward test of future discipline.¹⁶ Holding near the mid-2s while funding tuck-ins from cash flow confirms the discipline is structural. Drifting materially higher to fund larger acquisitions at elevated multiples would indicate the company has reverted to the roll-up instincts it was rewarded for abandoning.

↑ Back to Top

XI. Epilogue, Source Leads & Links

There is a certain symmetry in how this story arrived at July 2026. A company that began as a federal Job Corps contractor in Louisville, that spent four decades in the least glamorous corner of American healthcare, that was bought and sold by two private equity firms, that was leveraged to roughly six times EBITDA and then humiliated on its first day as a public company — that company joined the S&P MidCap 400 on July 17, 2026, replacing an industrial gas equipment manufacturer that had been acquired.³

Index inclusion is not an achievement in the operating sense. It is a mechanical consequence of market capitalization and liquidity. But it is a useful marker of institutional acceptance, and it closes a loop that opened when the IPO priced $2.00 below its range.

What the market has done, in effect, is re-underwrite BrightSpring from one category into another. In January 2024 it was priced as a levered sponsor-controlled roll-up with Medicaid exposure. In July 2026 it is priced as a deleveraged specialty pharmacy and clinical home health platform with a demonstrated acquisition capability and a defensible independent position in oncology distribution.

Both descriptions were true of the same underlying assets. That is the uncomfortable and instructive part. The operating improvements were real — 28.2% revenue growth and 34.2% adjusted EBITDA growth in 2025 are not narrative constructs, and $490 million of operating cash flow against $24 million the prior year is not an accounting trick.⁸ But a large share of the equity return came from moving the company from a category the market discounts into one it does not, by selling one division and repaying debt. Those levers have now been pulled.

From here, the case rests on things that are genuinely harder and genuinely uncertain. Whether Onco360 continues winning manufacturer designations against three vertically integrated competitors who would like the business. Whether the acquired home health branches deliver the full-year contribution management has guided to and hold their clinical staff. Whether CMS's multi-year effort to claw back home health payment continues on its current trajectory or accelerates. Whether the company can keep absorbing federal drug-pricing headwinds through procurement and automation without eroding the margin expansion it has delivered. And whether a management team that has been rewarded handsomely for discipline behaves the same way now that its currency is expensive and its balance sheet is clean.

Those are the questions. The record to date suggests a team that has answered similar questions well. The valuation suggests a market that expects them to keep doing so.

For readers who want to go to the primary material: the Q1 2026 earnings release and call transcript contain the divestiture accounting, the LDD count, the IRA quantification, and the acquired-branch contribution.¹⁶¹⁵ The full-year 2025 results release provides the clean segment revenue and EBITDA split for continuing operations, the revenue-per-script series, and the leverage progression.⁸ The FTC's January 2026 complaint and June 2026 consent order document the competitive structure of the IDD sector and the exact operational concessions required.[^19]¹⁷ The company's SEC filings and investor relations portal hold the annual reports, proxy statements, and quarterly materials against which every claim in this piece can be checked.²⁰²¹

BrightSpring Health Services

Table of Contents

BrightSpring Health Services: The PE Roll-Up That Actually Compounded

I. Introduction & Episode Roadmap

II. The Legacy of ResCare: James R. Fornear and the IDD Roots (1974–2016)

III. The Catalyst: Jon Rousseau and the Clinical Acuity Shift (2016–2018)

IV. The KKR Masterplan: PharMerica, Walgreens, and Vertical Integration (2017–2019)

V. The Private Equity Era: Roll-Ups, Leverage, and the IPO Skepticism (2019–2024)

VI. Smashed Expectations: The Explosion of Onco360 and Specialty Pharmacy

VII. The Grand Divestiture: Selling ResCare Community Living to Sevita

VIII. Segment Economics & Competitive Benchmarking

IX. Playbook: Business & Investing Lessons

X. Analysis: Porter's 5 Forces, Helmer's 7 Powers, and the Bull vs. Bear Case

Helmer's 7 Powers applied

Porter's Five Forces

The bull case, tested

The bear case, taken seriously

Management credibility

The KPIs that actually matter

XI. Epilogue, Source Leads & Links

References